Insider Buying: Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases 5,400 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 5,400 shares of the company's stock in a transaction that occurred on Thursday, April 17th. The shares were acquired at an average price of $8.98 per share, with a total value of $48,492.00. Following the acquisition, the chief executive officer now owns 5,567,002 shares in the company, valued at $49,991,677.96. This trade represents a 0.10 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Monday, April 7th, Snehal Patel purchased 3,600 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $9.10 per share, for a total transaction of $32,760.00.
• On Friday, April 4th, Snehal Patel bought 5,500 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $8.73 per share, for a total transaction of $48,015.00.

Greenwich LifeSciences Stock Down 4.4 %

Shares of GLSI stock traded down $0.46 on Friday, hitting $9.98. The stock had a trading volume of 62,962 shares, compared to its average volume of 45,347. The company has a market cap of $132.47 million, a PE ratio of -12.47 and a beta of 1.76. The business has a 50 day moving average price of $10.63 and a 200 day moving average price of $12.24. Greenwich LifeSciences, Inc. has a one year low of $8.06 and a one year high of $18.75.

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.40). Equities research analysts expect that Greenwich LifeSciences, Inc. will post -0.8 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright increased their price objective on Greenwich LifeSciences from $38.00 to $39.00 and gave the stock a "buy" rating in a research note on Monday, April 21st.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers boosted its position in Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock valued at $92,000 after purchasing an additional 3,168 shares in the last quarter. GAMMA Investing LLC purchased a new stake in shares of Greenwich LifeSciences during the first quarter valued at about $126,000. Bank of America Corp DE boosted its holdings in shares of Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock valued at $82,000 after buying an additional 1,322 shares in the last quarter. Northern Trust Corp grew its position in shares of Greenwich LifeSciences by 17.3% in the 4th quarter. Northern Trust Corp now owns 87,423 shares of the company's stock worth $982,000 after buying an additional 12,923 shares during the last quarter. Finally, Barclays PLC grew its position in shares of Greenwich LifeSciences by 12.7% in the 4th quarter. Barclays PLC now owns 9,648 shares of the company's stock worth $108,000 after buying an additional 1,088 shares during the last quarter. 4.16% of the stock is currently owned by hedge funds and other institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.